PROK
ProKidney Corp.
Biotechnology · Healthcare · United States
1.30
close · 2026-10-30
value
11
cheaper than peers11
quality
54
stronger fundamentals54
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -17.8% | 46 |
| cash flow yield, 3 years ago | -15.3% | 34 |
| earnings yield, 2 years ago | -44.0% | 32 |
| cash flow yield, 2 years ago | -24.0% | 31 |
| cash flow yield, latest year | -26.2% | 28 |
| earnings yield, latest year | -40.2% | 26 |
| earnings yield, 1 year ago | -47.9% | 24 |
| cash flow yield, 1 year ago | -30.2% | 24 |
| price to sales | 631.96× | 5 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.6% | 89 |
| return on equity | -59.0% | 43 |
| revenue growth | -32.1% | 26 |
3 of 4 measures available
Facts
| market cap | $517M |
| free cash flow | -$83.8M |
| employees | 231 |
| first trade | 2021-06-30 |
| next earnings | not reported |
| fundamentals updated | 2026-08-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.52 | -0.62 | -0.57 | -0.23 |
| free cash flow | -$135.3M | -$155.9M | -$124.3M | -$78.9M |
| net income | -$69.0M | -$61.2M | -$35.5M | -$108.0M |
| revenue | $893,000 | $76,000 | $0 | $0 |